Korys’ Post

52North Achieves Historic Milestone! 🌟🚀 We are thrilled to announce that cohort 4 Clinical Entrepreneur Dr Saif Ahmad and the team at 52North have secured $6 million in new funding! This includes a landmark first-ever investment deal co-led by funds linked to both US and UK hospitals, KHP Ventures and Cedars-Sinai, along with a $1.5 million grant from NIHR (National Institute for Health and Care Research). Launched in 2018, 52North is dedicated to creating affordable technologies that empower patients and enable decentralised clinical decision-making. Their innovative product, Neutrocheck®, is a finger prick blood test and digital platform providing rapid and reliable at-home results, helping doctors identify chemotherapy patients at risk of sepsis.💡 This is a monumental achievement for the team, setting the stage for more transatlantic partnerships in the future. We eagerly anticipate the positive impact this funding, new partnerships, and investors will have on patients and their families. ❤️ To read our full case study on Dr Saif Ahmed and 52North, please visit our website at https://lnkd.in/evbsEfwU 52North - creators of Neutrocheck® Umaima Malik Ahmad NHS England Tony Young Polly Sullivan Lucy Dentice Emily Lloyd Alex Ganzerla Accelerated Access Collaborative Tamsin H. #NHSCEP #NHS #Innovation #Entrepreneur #CancerCare #Sepsis #Healthcareimprovement #Funding #Investment #MedicalDevice #MedTech #TechNews #ARUProud #Community #Collaboration

The longevity market focused on extending the human lifespan and improving health in later years, is rapidly expanding. The sector attracts significant investments from VCs, the pharmaceutical industry and tech giants, aiming to revolutionize the way we approach aging and age-related diseases. It is great to see more longevity-focused events appearing on the conference scene - meeting to discuss, share knowledge and network is crucial for all of us. In a few weeks, during London Tech Week on June 10-11, LongeVC managing partner Sergey Jakimov will attend one of the panels during the Founders Longevity Forum. The event, co-organized in partnership with Longevity.Technology, will gather some of the industry’s greatest leaders, including Insilico Medicine CEO and Head of LongeVC Advisory Board Alex Zhavoronkov, Bruno Balen, founder of Ani Biome, one of LongeVC portfolio companies, Todd White (VitaDAO), Aubrey de Grey (Longevity Escape Velocity (LEV) Foundation), Petr Sramek (LongevityTech.fund), Bhuvan Srinivasan (Ultrahuman), Christin Glorioso, MD PHD (NeuroAge Therapeutics), Joanna Bensz (Longevity Center Europe) and more. If you’d like to connect with Sergey Jakimov or Garri Zmudze during the event, drop them a message or contact us via [email protected]. https://lnkd.in/d3cDSEe6 #Longevity #BiotechInvesting #FoundersForum #London Founders Forum Group Carolyn Dawson

In this week’s episode Meri Beckwith shares his journey from the world of investing to breaking the bottlenecks when it comes to clinical trials as he builds the anti-CRO for life science pioneers. We discussed: 🔄 Transitioning from venture capital into healthtech 💼 Investor vs Founder Traits, Personality and Mindset 🌱 The origin story of Lindus Health 🏗️ The first few days/weeks of building Lindus Health 🚧 Barriers to entering the pharma industry as a new startup 🔒 Securing the first clinical trial with Habitual 🍾 The bottle necks of clinical trials 🔍 The process of recruiting patients for clinical trials ❌ Where central organisations and institutions go wrong for clinical trials 🤖 The role of AI in the pharma industry 💰 Fundraising a $18m Series A with investments from the likes of Peter Thiel 🔒 How to prevent being replaced by the board and investors 🏢 How to build a healthy culture and team 🤝 How to become a great CEO and deal with co-founder conflicts 💊 Why do pharma need CROs for clinical trials and why become the anti-CRO Link in the comments!

CHF 40’000 for Adjust Medical, JOSEPHA, and dEEGtal. These three projects were selected at Venture Kick's second financial and entrepreneurial support stage. https://lnkd.in/dv7vEGgD   Meet the 3 winning startups and their founders:   Co-Founders: Youssef Biadillah, Vitaliy Verin, Giovanni Leo, and Aristotelis Panos | Adjust Medical - A new differentiated treatment fo Mitral Valve Regurgitation. https://lnkd.in/eagzgivK   Silvan Weder (CEO) and Josef Gitterle (CPO) | JOSEPHA - Providing personalized advice on every product on the internet. https://lnkd.in/duXGGEUr   Stefano Gallotto (CTO), Margitta Seeck (Co-Founder and Advisor), and Eric Ménétré (CEO) | dEEGtal - AI-powered epilepsy diagnosis software for rapid results. https://lnkd.in/dgZx2bAr   #VentureKick #SwissStartups

After a productive networking break in the Great Room Foyer, we now have the “Medtech by the Numbers” Panel Session, moderated by Jennifer McMahon, Partner at Seroba.: • Inga D. Deakin, Principal, Molten Ventures • Megan MacDonagh, Vice President, SV Health Investors • Anne Portwich, Partner, EQT Life Sciences  • Sylvain Sachot, Partner, Asabys Partners 2023 life science investment went down across the board, in biotech and medtech equally, but in diagnostics and healthtech to a greater degree. A panel of European VCs discusses what’s in store for 2024. The number of up-rounds is down, which is a negative for VC firms supporting early-stage companies. The situation needs to change in order to reward early investment, the lifeblood of medtech innovation. We are seeing a lot of structured deals, option deals with many milestones. It does look good when a strategic is interested in a company, and it provides a path for exit. But it is a two-sided sword.   Remain informed on new articles, conference updates and more with our helpful medtech community newsletter. Subscribe here: https://bit.ly/42KHJKI

We are celebrating the successful closing of an additional $2.32 Million in Seed Plus funding, closing this round out $500,000 oversubscribed at $5 Million to address underserved #pelvichealth issues. This milestone reflects progress toward our mission to empower women & clinicians with a new gold standard in conservative care for #urinaryincontinence. We extend our deep appreciation to our outstanding partner, Boomerang Ventures for leading this investment round, and we warmly welcome new investors Pier 70 Ventures, Life Science Angels, Orange County Tech Coast Angels MedTech, and Blue Pacific Capital! "Completing this round is an important step in continuing Pelvital's unwavering dedication to provide women with innovative solutions for pelvic health, including the treatment of SUI," says Lydia Zeller, President and CEO of Pelvital. "This funding will play a crucial role in accelerating our commercialization of Flyte with a strong emphasis on expanding payor coverage, enhancing clinical education and clinician awareness, and advocating for upstream screening for UI in primary care and OB/GYN." With this close we are honored to welcome Preetha Ram, PhD, Managing Partner at Pier 70 Ventures, to the Pelvital Board of Directors.   "Joining Pelvital's Board alongside this investment round is truly an honor," she shares. "Pier 70 and I are thrilled to be part of this transformational opportunity, as Pelvital's mission aligns beautifully with our dedication to support disruptive technologies that shake up the status quo in healthcare. Pelvital's pioneering work is shaping a future where women's health receives the attention and innovation it deserves with novel medical devices like Flyte." With two published clinical trials validating Flyte's efficacy, we're excited to offer a groundbreaking treatment option for women. Learn more at Flytetherapy.com. #funding #Innovation #WomenInHealthcare Read the full release here: https://lnkd.in/ggkavYRq

For this week's Forbes 30 Under 30 Newsletter, I spoke with the cofounders of Genetesis, a Cincinnati-based biotech company. The biggest takeaway from our conversation? Rely on those around you to grow. The three childhood friends came together in 2013 with a mission to make it easier (and more accurate) to get a diagnosis at the doctors office, with a special focus on cardiology. They're backed by $40 million from investors like Mark Cuban today, but it took years of working with local medical experts, conducting tests with their technology on friends and family, and participating in local pitch competitions and entrepreneurship groups to finalize their proof of concept. Read more about their journey from high-school founders to the Forbes 30 Under 30 list and $40 million in funding here. *Do you know someone else from the Cincinnati area making waves in their industry? We're looking for young founders and leaders for this year's 30 Under 30 Local Cincinnati list. Let us know if you have any nominations by emailing u30lister[at]forbes[dot]com with their name and bio today.* https://lnkd.in/ehH-sbn3 Peeyush Shrivastava, Manny Setegn, Vineet Erasala

𝐁𝐥𝐚𝐜𝐤 𝐇𝐢𝐬𝐭𝐨𝐫𝐲 𝐌𝐨𝐧𝐭𝐡 𝐭𝐚𝐥𝐤: Dr Jason Mellad, Start Codon The Department is proud to host Dr Jason Mellad, co-founder and CEO of Start Codon, as our Black History Month talk. This is an in-person talk only, visitors are welcome to attend. 𝐓𝐚𝐥𝐤 𝐓𝐢𝐭𝐥𝐞: Young, Gifted and Black   𝐁𝐢𝐨𝐠𝐫𝐚𝐩𝐡𝐲: Jason is Start Codon's Co-Founder and CEO and is responsible for developing and implementing its strategy, managing and dealing with investor relations and working closely with Start Codon's portfolio companies to set and monitor their progress and to help them secure further investment and non-dilutive finance. Jason regularly sits as a director observer on the boards of Start Codon's portfolio companies.   Jason is a scientist entrepreneur passionate about translating innovative technologies into more effective therapies and better patient outcomes. Previously, he was CEO of Cambridge Epigenetix, which developed a proprietary epigenetic biomarker discovery platform for the development of new diagnostic assays and the identification of novel drug targets. While at Cambridge Epigenetix, Jason transformed the research tools company into a leading liquid biopsy player and led two successful fundraisers (Series B and C) for a total of $49.8m.    A full biography can be found here: https://startcodon.co/team.   𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐲: Start Codon is a venture capital investor and venture builder based in Cambridge, England. It supports aspiring entrepreneurs in developing and commercialising their disruptive innovations. In doing so, it aims to help them craft their vision into thriving companies that improve people’s lives and address unmet needs.   They invest a minimum of £250,000 into each of our portfolio companies. In addition, all of their portfolio companies and their founders are enrolled on Start Codon’s unique and innovative venture-building programme. Through this, the company provide a combination of access to a dedicated and experienced team, mentors who are leaders in their field, and an extensive network of investors, pharma and biotech partners, commercial partners and collaborators and facilities. #BHM #BlackHistoryMonth #Entrepreneurship #Pharmacology #Cambridge

How does Intuitive’s support differ when backing companies outside its core focus areas versus those closely aligned with its primary business units? In this clip, Murielle Thinard McLane discusses her approach to evaluating and supporting companies outside of Intuitive’s core focus areas. She highlights the importance of transformative vision, a strong syndicate, and early product-market considerations rather than relying on traditional, later-stage commercial handoffs. This forward-thinking perspective ensures that innovation and market strategy are integrated from the outset. At LSI Europe ‘24, we brought together Amber Therapeutics Co-Founder & CEO, Aidan Crawley, and the investors that were part of the landmark $100 million Series A funding round to discuss how Amber Therapeutics is revolutionizing the future of neuromodulation for mixed urinary incontinence. Tune into the full panel, “Amber Therapeutics: Landmark $100M Series A” to hear more from this incredible group of panelists: • Henry Peck (Moderator), Chief Business Officer, LSI • Aidan Crawley, Co-Founder & CEO, Amber Therapeutics • Caroline Gaynor, Partner, Lightstone Ventures • Murielle Thinard McLane, President & Managing Partner, Intuitive Ventures • Liliane Chamas, PhD, Healthtech Principal, Oxford Science Enterprises Want to attend our next event? LSI USA ‘25 will be held March 17th-21st in Dana Point, California. Apply today on our website.

I was excited to join the LifeArc Translational Science Summit yesterday to explore how I can support new companies scaling operations and improving efficiency to accelerate bringing medicines to market. A great opportunity for networking and staying current. #LifeArc #Consultancy #NetworkingOpportunity 🚀💼✨ 🔬 Biotech ventures morning sessions🔬 The UK’s biotech sector - Surveying the landscape and opportunities for growth  🌟 Claire Terlouw (LifeArc) and Steve Bates OBE FMedSci (BioIndustry Association (BIA)) led a discussion on the impact of the BIA within the life science sector. Hearing firsthand accounts of crisis management scenarios navigated through the BIA reaffirms its critical role in our industry. Successfully navigating challenges like the R&D tax credits debacle and the Silicon Valley Bank collapse is truly inspiring. #LifeArc #BIA #LifeScience 💡🔬 Financial Strategies for the future – funding innovative life science companies  🚀 We moved to the world of financing strategies. Led by Claire Terlouw (LifeArc) with Arthur Franken (Gilde Healthcare), Neil White (Yosemite), Eliot Charles (SR One Capital Management), and Luc Dochez (Droia Ventures). My key takeaways :   💼 Learning about diverse investor types, tailored investment strategies, and the crucial balance of risks in decision-making. From technical to financial considerations, every aspect matters.   💡 Embrace rejections as learning opportunities, building resilience for future success in the competitive investment landscape. #InvestmentStrategies #ResilienceBuilding 📈 The CEO war room   🌟 A session led by Imran Hamid (LifeArc) who was joined by Hakim Yadi (Closed Loop Medicine), Mike Westby (RQ Biotechnology Limited), and Natalie Mount (Abingworth) who shared their war stories, lessons learned, and tips for aspiring entrepreneurs.  My key takeaways: 🚀 Embrace feedback..... even a 'no' decision will provide valuable learnings.  🤝 Understand the evolving role of the board and the importance of building trust and relationships. #EntrepreneurshipJourney #LessonsLearned #CEO #Feedback #Trust💡 I’ll share the afternoon sessions tomorrow! #LATSS2024 Great to see some familiar faces too Natalie Francis, Claudia Montiel Equihua, Nigel Huscroft, Ian Catchpole, Kathryn Chapman,